In early June, the China (Jinan) Hyaluronic Acid Industry Conference was held in Jinan, Shandong Province, China. During the conference, Bloomage Biotechnology (SH: 688363), a leading company in the hyaluronic acid industry, officially announced its Corporate Venture Capital (CVC) strategy and entered into a strategic cooperation agreement with Fuyuan Investment to jointly establish the first synthetic biofund in China.
*CVC refers to the investment activities conducted by enterprises through the establishment of venture capital departments or private equity venture capital funds, al …
